A 2-Year comparison of quality of life outcomes between Biomet stock and OMX custom temporomandibular joint replacements

Abstract

Purpose Alloplastic joint replacement is the mainstay treatment for end-stage temporomandibular joint (TMJ) disease. The aim of this study is to evaluate the 2 year quality of life (QoL) outcomes for patients who have undergone alloplastic TMJ total joint replacement with either custom or stock devices. Methods This was a retrospective cohort study of patients who had TMJ replacement with either Biomet stock or OMX custom prostheses. All patients were recruited from the patient database of a single surgeon, at a single location. QoL was assessed using a patient completed TMJ Surgery specific QoL (TMJ-S-QoL) questionnaire. Patients answered questions pertaining to pain, diet, speech and aspec..